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Glucose responseThe Rab-GTPase activating protein TBC1D1 is a paralog of AS160/TBC1D4. AS160/TBC1D4, a down-
stream effector of Akt, has been shown to play a central role in beta-cell function and survival.
The two proteins have overlapping function in insulin signalling in muscle cells. However, the
expression and the potential role of TBC1D1 in beta-cells remain unknown. Therefore, the aim of
this study is to investigate whether TBC1D1 is expressed in beta-cells and whether it plays, as
AS160/TBC1D4, a role in beta-cell function and survival. Using human and rat beta-cells, this study
shows for the ﬁrst time that TBC1D1 is expressed and phosphorylated in response to glucose in these
cells. Knockdown of TBC1D1 in beta-cells resulted in increased basal and glucose-stimulated insulin
release, decreased proliferation but no change in apoptosis.
Structured summary of protein interactions:
TBC1D1, glucagon and insulin colocalize by ﬂuorescence microscopy (View interaction)
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The mechanism and the signalling pathways that regulate
insulin secretion and beta-cell mass represent a critical issue for
understanding diabetes mellitus, a disease characterized in its
two major forms by a relative or absolute deﬁciency in the number
of pancreatic beta-cells. Studies that involved insulinoma cells and
animal models with genetic knockout of the insulin receptor, insu-
lin receptor substrates, and insulin-like growth factor I receptor
(IGFIR) provided evidence that insulin/IGFIR/PI3K signalling path-
ways mediate insulin action in beta-cells [1,2]. Moreover, these
studies demonstrated that activation of the insulin receptor and
insulin receptor substrate is required for the glucose effects on
beta-cell growth and survival. The complexity of insulin signalling
cascades is highlighted by the existence of multiple isoforms of tar-
get proteins implicated in metabolic and gene-regulatory events.
Rab-GTPase activating protein (Rab-GAP) AS160, also known as
TBC1D4, is a major downstream effector of insulin signalling in
insulin sensitive tissues (muscle and fat) and is implicated in
GLUT4 translocation [3].Recently, we showed that AS160/TBC1D4 is expressed and
phosphorylated in response to glucose in pancreatic human beta-
cells and is involved in glucose stimulated insulin secretion (GSIS),
proliferation and survival [4]. This study revealed that AS160/
TBC1D4 plays a central role in beta-cell function and survival, in
line with previous studies demonstrating that the insulin signal-
ling pathway plays a central role in beta-cells.
TBC1D1, a paralog of TBC1D4, has been shown to be expressed
in human skeletal muscle and to be involved in GLUT4 transloca-
tion after insulin stimulation or muscle contraction [5]. Moreover,
several studies have demonstrated a critical role for TBC1D1 in glu-
cose and lipid metabolism as well as in whole body energy homeo-
stasis [6]. Nevertheless, a genetic variant of TBC1D1 (R125W) is
associated with predisposition for human obesity [7]. There is
approximately 50% homology between AS160/TBC1D4 and
TBC1D1, but the Rab-GAP domains are almost identical, thus
implying that the 2 proteins might have some overlapping function
[8]. Indeed, it has been shown that in their non-phosphorylated
state AS160/TBC1D4 and its paralog TBC1D1 retain GLUT4 in intra-
cellular vesicles by keeping target Rabs in an inactive, GDP-bound
state. When TBC1D1/4 Rab-GAP activity is inhibited by phosphor-
ylation, GLUT4 vesicles are released for translocation to the cell
surface, leading to increased transport of glucose across the cell
membrane [3]. In skeletal muscle and adipose tissue, insulin
treatment and subsequent AMPK activation induce a speciﬁc
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phosphorylation proﬁle determines its speciﬁc activation [9].
Moreover, the presence only on TBC1D1 and not on TBC1D4 of
an AMPK dependent site of phosphorylation (Ser-237 in humans
and Ser-231 in rats) contributes in part to explain its unique regu-
latory properties [10]. We and others have demonstrated in the
past that a parallel can be made between the regulation of GLUT4
and insulin granule trafﬁcking [1,11].
The aim of the present study was to investigate whether
TBC1D1 is expressed and phosphorylated in response to glucose
in primary human and rat sorted beta-cells and if so to determine
its involvement in GSIS as well as in beta-cell proliferation and
survival.2. Methods
2.1. Islets, primary beta-cell puriﬁcation and culture
Islets of Langerhans were isolated by collagenase digestion of
pancreas from adult male Wistar rats. This study was conducted
and the animal sacriﬁced with the authorization from Geneva State
Veterinarian’s Ofﬁce. Beta-cells were separated from non-beta-
cells by autoﬂuorescence-activated cell sorting (FACS) using a
FACSVantage (Becton Dickinson, Franklin Lakes, NJ) as described
previously [12]. Sorted rat beta-cells purity was assessed by immu-
noﬂuorescence staining for insulin. Sorted rat beta-cells were cul-
tured in DMEMmedium containing 11 mmol/l glucose, 0.05 mg/ml
gentamicin, 100 U/ml penicillin, 100 mg/ml streptomycin, and 10%
fetal calf serum (Sigma–Aldrich, St. Louis, MO, USA). Sorted rat
beta-cells were cultured on plastic dishes coated with extracellular
matrix derived from 804G cells as described elsewhere [12] and
were left for 24 h to adhere and spread before initiation of the
experiments.
Human islets were kindly provided by the Cell Isolation and
Transplant Centre of the University of Geneva, through JDRF award
31-2008-413 (ECIT Islet for Basic Research Program). Human islets
were dispersed by Acutase (PAA Laboratories, Pasching, Austria)
and beta-cells were sorted by FACS after labelling with Newport
Green and exclusion of ductal cells and dead cells using a FACSVan-
tage (Becton Dickinson) as described before [12]. The purity of the
beta-cells was performed for each preparation using immunoﬂuo-
rescence staining for insulin and glucagon.
2.2. RNA interference mediated knockdown of endogenous TBC1D1
by transient transfection
Knockdown of TBC1D1 in rat primary beta-cells was
achieved by transfection with speciﬁc small interfering
RNA (Tbc1d1RSS323178(3_RNAI) + Tbc1d1RSS323179(3_RNAI) +
Tbc1d1RSS323180(3_RNAI) from Invitrogen, Life Technologies,
Grand Island, NY, USA) and control siRNA (SignalSilence Control
siRNA, Cell Signaling Technology, Danvers, MA, USA) using a
method described previously [13]. In brief, liposome–siRNA
(Lipofectamine 2000 from Life Technologies and 100 nM siRNA)
was prepared in 200 ll opti–Modiﬁed Eagle’s Medium as described
by the suppliers (Life Technologies).
2.3. RNA extraction, library preparation, sequencing and read mapping
Sorted beta-cells and islets were centrifuged, the supernatant
was removed and the pellet disrupted in RLT buffer (RNeasy,
Qiagen, Hilden, Germany). Total RNA was prepared according to
the standard RNeasy protocol. Total RNA library construction,
RNA sequencing and read mapping was performed as described
in detail elsewhere [14].2.4. Expression quantiﬁcation
GENCODE annotation v10 was used to assign ﬁltered reads to
their corresponding exons and genes. The gene counts were incre-
mented non-redundantly i.e. reads overlapping two exons are
counted once to the total count sum per gene. Resulting raw gene
counts were normalized to gene length (sum of exons) and
sequencing depth i.e. RPKM – reads per kilobase per million
mapped reads [14].
2.5. Western blotting
Phosphorylation and expression of TBC1D1, or expression of
CDK4, Akt and actin was determined by Western blot analysis.
Beta-cell protein lysate was separated by SDS–PAGE, transferred to
Immobilon-Pmembranes (Millipore), and probedwith anti-TBC1D1
or anti-pTBC1D1 (Serine 231 and Threonine 596, developed byMak-
oto Kanzaki) and secondary horseradish peroxidase-conjugated
antibodies. Anti-actin was obtained from Merck Millipore, (Zug,
Switzerland), anti-CDK4 from Santa Cruz Biotechnology Inc. (Hei-
delberg, Germany) and anti-Akt from Cell Signaling.
2.6. Insulin secretion
For acute insulin release in response to glucose, primary rat
beta-cells were washed, preincubated for 2 h (2.8 mmol/l glucose)
and incubated in Krebs–Ringer bicarbonate Hepes (KRB) buffer
(0.5% BSA) containing 2.8 mmol/l glucose for 1 h followed by 1 h
incubation in KRB containing 16.7 mmol/l glucose or by 10 min
incubation with KRB containing 30 mM KCl. Islet insulin was ex-
tracted with 0.18 M HCl in 70% ethanol for determination of insulin
content. Secreted insulin and insulin content were measured by
radioimmunoassay using rat insulin standards.
2.7. Cell proliferation and death
Sorted rat beta-cells were established in monolayer on dishes
coated with 804G-ECM [12]. Two days after transfection, BrdU
was added to the cells for 24 h. The incorporated BrdU was de-
tected with an anti-BrdU antibody according to the manufacturer’s
instructions (BrdU kit; Roche Diagnostics, Rotkreuz, Switzerland)
and the beta-cells were co-stained with an anti-insulin antibody.
The free 3-OH strand breaks resulting from DNA degradation were
detected by the terminal deoxynucleotidyl-transferase-mediated
deoxyuridine 5-triphosphate nick-end labeling (TUNEL) technique
according to the manufacturer’s instructions (in situ cell death
detection kit; Roche Diagnostics), The beta-cells were co-stained
with an anti-insulin antibody. The numbers of proliferative or
apoptotic cells were determined using a ﬂuorescent microscope.
For each condition in each individual experiment, over 1000 cells
were analyzed.
2.8. Immunoﬂuorescence
TBC1D1 and phospho-TBC1D1 were detected with speciﬁc anti-
TBC1D1, anti-phospho-TBC1D1-Ser-231/237 and anti-phospho-
TBC1D1-Thr-596 antibodies developed by us (Dr. Makoto Kanzaki)
according to standard procedures for ﬁxation and confocal ﬂuores-
cence microscopic observation. Beta- and alpha-cells were identi-
ﬁed by insulin and glucagon immunoﬂuorescence respectively.
2.9. Statistical analyses
Data are expressed as means ± S.E.M., with the number of
individual experiments presented in the ﬁgure legends. All data
were tested for normality and analyzed with PRISM (GraphPad,
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test and ANOVA with Bonferroni post hoc test for multiple
comparison analysis. Signiﬁcance was set as P < 0.05.
3. Results
3.1. TBC1D1 is expressed in pancreatic islets and primary beta-cells
and is phosphorylated in response to glucose
TBC1D1 is a paralog of TBC1D4 and like it, is phosphorylated in
response to insulin in skeletal muscle and adipocytes [3,15]. Using
RNA sequencing, we report for the ﬁrst time that TBC1D1 is ex-
pressed at the mRNA level in human islets and also in FACS-sorted
primary human beta-cells (86.7 ± 6.8% insulin positive cells). With
this technique, the number of mRNA copies for each gene was ob-
tained, allowing to directly compare the expression of genes of
interest. We observed that the expression of TBC1D1 was lower
than AS160/TBC1D4 in human sorted beta-cells but similar for
the 2 isoforms in human islets (Fig. 1A). Moreover, we observed
in dispersed human islet cells co-stained for TBC1D1 (red), insulin
(green) and glucagon (cyan) that TBC1D1 co-localizes with both
glucagon and insulin (Fig. 1B). These immunoﬂuorescence results
conﬁrm that TBC1D1 is expressed at the protein level in both these
human islets cell types.
We use a silencing approach in order to study the role of
TBC1D1 in beta-cells. However, in our hands siRNA transfection
of human beta-cells is not feasible. Therefore we used primary
rat beta-cells for this purpose, having shown previously that siRNA
transfection is efﬁcient in these cells [4,13]. We analysed TBC1D1
protein expression and phosphorylation in rat primary sortedA 
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Fig. 1. TBC1D1 expression and phosphorylation. (A) TBC1D1 and AS160/TBC1D4mRNA ex
kilobase per million mapped reads (RPKM). ⁄P < 0.05 as tested by ANOVA followed by Bon
TBC1D1 (red), insulin (green), glucagon (cyan) and nucleus (blue). (C) Representative im
Ser-231 or phosphorylated TBC1D1 Thr-596 (green) and DAPI (blue) under basal conditio
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(Fig. 1C). We investigated the phosphorylation of 2 key sites on rat
TBC1D1: Thr-596 and Ser-231. TBC1D1 Thr-596 is a phosphoryla-
tion site identical to Thr-642 on AS160/TBC1D4. We have observed
that AS160/TBC1D4 Thr-642 is phosphorylated in response to glu-
cose in beta cells and that this phosphorylation is Akt dependent
(unpublished observation). TBC1D1 Ser-231 is the rat phosphoryla-
tion site equivalent to human Ser-237, a motif recognized by AMPK
that has been shown to be phosphorylated in muscle after exercise
and to be involved in Glut4 trafﬁcking [9]. TBC1D1 Ser-231 is phos-
phorylated in rat beta-cells already after 10 min glucose stimula-
tion (Fig. 2A) and this phosphorylation is still present after
60 min glucose stimulation (Figs. 1C and 2B). By contrast, 10 min
glucose stimulation is not sufﬁcient to induce TBC1D1 Thr-596
phosphorylation (Fig. 2C) whereas this site is phosphorylated after
60 min glucose stimulation (Figs. 1C and 2D). Taken together, these
data on TBC1D1 expression and phosphorylation after glucose
stimulation suggest that this protein might play a role in beta-cell
response to glucose.
3.2. Modulation of beta-cell function and proliferation by TBC1D1
silencing
To study the biological function of TBC1D1, primary rat beta-
cells were transfected with siRNA against TBC1D1 or scrambled
siRNA (control). Cells transfected with TBC1D1 siRNA showed a
70% reduction in TBC1D1 protein expression (Fig. 3A). In cells with
such reduced TBC1D1 expression, basal insulin as well as glucose
stimulated insulin secretion were modestly increased without
any change in fold-stimulation (Fig. 3B) and total insulin contentpTBC1D1 T596  1D1 S231 
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pression in human islets (n = 11) and sorted beta-cells (n = 6) presented as reads per
ferroni post hoc test. (B) Representative images of dispersed islet cells co-stained for
ages of primary rat sorted beta-cells co-stained for TBC1D, phosphorylated TBC1D1
ns (2.8 mmol/l glucose) or after 60 min stimulation with 16.7 mmol/l glucose. Scale
A 
pTBC1D1 Thr 596 
TBC1D1 
C 
Actin 
pTBC1D1 Thr 596 
2.8 16.7 
Glucose (mmol/l) 
Glucose (mmol/l), 10 min 
D 
2.8 16.7 
Glucose (mmol/l), 60 min 
Glucose (mmol/l) 
pTBC1D1 Ser231 
2.8 16.7 
Glucose (mmol/l), 10 min 
B 
TBC1D1 
pTBC1D1 Ser231 
2.8 16.7 
Glucose (mmol/l) 
Glucose (mmol/l), 60 min 
Glucose (mmol/l) 
Actin 
ph
os
ph
o-
TB
C
1D
1 
Se
r 
23
1/
TB
C
1D
1 
(A
U
)
2.8 16.7
0
2
4
6
*
ph
os
ph
o-
TB
C
1D
1 
Th
r 
59
6/
TB
C
1D
1 
(A
U
)
2.8 16.7
0
2
4
6
*
TBC1D1 
Actin 
Actin 
TBC1D1 
Fig. 2. TBC1D1 phosphorylation in response to glucose. (A) Representative Western blot and quantiﬁcation of TBC1D1 Ser-231 phosphorylation in primary rat beta-cells at
2.8 mmol/l glucose (open bars) or after 10 min stimulation with 16.7 mmol/l glucose (closed bars) (n = 3). (B) Representative Western blot and quantiﬁcation of TBC1D1 Ser-
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Western blot and quantiﬁcation of TBC1D1 Thr-596 phosphorylation in primary rat beta-cells at 2.8 mmol/l glucose (open bars) or after 10 min stimulation with 16.7 mmol/l
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18 S. Rütti et al. / FEBS Letters 588 (2014) 15–20(data not shown). These results suggest that TBC1D1 is not essen-
tial for GSIS in sorted rat primary beta-cells, in marked contrast to
our earlier results documenting a direct role of AS160/TBC1D4 in
this process [4]. We also stimulated the beta-cells with KCl which
induces calcium inﬂux and thereby insulin secretion indepen-
dently of glucose metabolism. Knockdown of TBC1D1 totally
prevented KCl induced insulin secretion (Fig. 3C).
To investigate the impact of TBC1D1 silencing on rat primary
beta-cell apoptosis and proliferation in culture, cell death was
quantiﬁed using TUNEL assay and cell replication was assessed
by BrdU incorporation over 24 h. Knockdown of TBC1D1 did not
affect beta-cell death (Fig. 4A and B). However, proliferation of
primary rat beta-cells transfected with TBC1D1 was dramatically
decreased when compared to cells transfected with scrambled siR-
NA (Fig. 4C). This marked reduction in proliferation when TBC1D1
is knocked down was also observed with elevated glucose concen-
trations in the rat beta-cell culture media (22 mM or 33 mM glu-
cose, data not shown). We also investigated the expression of 2
proteins implicated in beta-cell survival and proliferation, Akt
and Cdk4; neither was inﬂuenced by TBC1D1 knockdown.
4. Discussion
We have recently demonstrated that TBC1D4/AS160 is
expressed in human and rodent pancreatic beta-cells andphosphorylated after glucose stimulation [4]. We further estab-
lished that this protein is involved in glucose induced insulin
secretion, proliferation and survival of primary sorted beta-cells
[4]. TBC1D1 and AS160/TBC1D4 have signiﬁcant sequence similar-
ity and overlapping function in insulin responsive tissues [8]. Nev-
ertheless, the presence only on TBC1D1 and not on TBC1D4 of an
AMPK dependent site of phosphorylation on Ser-231 in the rat pro-
tein studied here (corresponding to Ser-237 in the human protein)
may contribute towards its unique regulatory properties [10]. In
the present study, we reveal for the ﬁrst time that TBC1D1 is ex-
pressed and phosphorylated upon glucose stimulation in human
islets, as well as in human and rat isolated beta-cells. Quantiﬁca-
tion of mRNA levels by RNA sequencing indicates that TBC1D1 is
less abundant than TBC1D4/AS160 in beta-cells but comparable
in islets. The higher levels of TBC1D1mRNA in islets than beta-cells
suggest relatively greater expression in islet non-beta-cells (com-
posed of approximately 60% alpha-cells) or in exocrine cells that
might contaminate human islet preparations. Our results were
supported by immunoﬂuorescence staining of dispersed human
islet cells where we observed the expression of TBC1D1 at the
protein level in beta- as well as alpha-cells.
Since TBC1D1 is expressed and phosphorylated in response to
glucose in rat primary beta-cells, we have used these cells to study
the role of TBC1D1 in beta-cell function, proliferation and survival.
Several studies have shown that a parallel mechanism could be
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20 S. Rütti et al. / FEBS Letters 588 (2014) 15–20observed between Glut4 and insulin vesicle trafﬁcking [16]. We re-
port here for the ﬁrst time that two key TBC1D1 phosphorylation
sites, Ser-231 (AMPK dependent) and Thr-596 (probably Akt
dependent), are phosphorylated in response to glucose, suggesting
that TBC1D1 is implicated in the beta-cell function. However, Ser-
231 is phosphorylated already after 10 min glucose stimulation,
whereas Thr-596 is only phosphorylated after 1 h of stimulation.
The kinetics of phosphorylation of the 2 phospho-speciﬁc sites in
response to glucose suggests either that TBC1D1 interacts with dif-
ferent kinases or that different stimuli are involved (glucose vs
insulin/IGF2). Our data suggest that AMPK and Akt are involved
in the early (Ser-231) and late (Thr-596) glucose-stimulated
TBC1D1 phosphorylation events respectively. It is postulated that
downstream signalling cascades may impact differently on beta-
cell function. These cascades are multiple, complex and
overlapping, both in terms of insulin secretion [17] and beta-cell
proliferation [18] which make their identiﬁcation complex.
In insulin target tissues, TBC1D1 and AS160/TBC1D4 phosphor-
ylation inhibits their Rab-GAP activity. Therefore, silencing of
TBC1D1 mimics this phosphorylation and inactive status. Knock-
down of TBC1D1 mildly affected beta-cell function by increasing
to a small and comparable extent both basal and stimulated insulin
secretion, while we have shown that AS160/TBC1D4 was a key reg-
ulator of insulin secretion [4]. This suggests that TBC1D1 might
interact with speciﬁc Rab proteins distinct from those downstream
of TBC1D4. Moreover, beta-cells with decreased TBC1D1 expres-
sion were unable to respond to KCl stimulated insulin secretion.
Overall, our results suggest that TBC1D1 gets phosphorylated in re-
sponse to glucose stimulation in beta-cells without playing a major
role in glucose stimulated insulin release. However, it appears
essential for calcium mediated insulin release in response to direct
depolorization by KCl. The apparent discrepancy between these
ﬁndings is perhaps explained by the well-documented ability of
glucose to elicit insulin secretion through increased cytosolic cal-
cium while also activating a calcium-independent potentiating
pathway [19] that would appear not to require TBC1D1. In sum-
mary, our data suggest that the 2 paralog proteins, TBC1D1 and
4, have distinct roles in the regulation of insulin secretion; TBC1D1
plays a role in the maintenance of baseline insulin secretion and is
essential for calcium-mediated secretion, whereas AS160/TBC1D4
plays a more central role in glucose stimulated insulin secretion.
Decreased protein expression of TBC1D1 inhibited beta-cell
proliferation without affecting survival, while AS160/TBC1D4 is in-
volved in both beta-cell survival and proliferation suggesting again
that these 2 proteins have non-redundant functions [4]. The strong
decrease in beta-cell proliferation when TBC1D1 is knocked down
seems to be independent of the glucose concentration present in
the media, suggesting that TBC1D1 plays a central role in beta-cell
proliferation. However, when looking at the expression of proteins
involved in beta-cell survival and in the cell cycle, knockdown of
TBC1D1 does not inﬂuence their expression. Nevertheless, TBC1D1
might interact with protein complexes involved in the regulation
of the cell cycle.
In conclusion, this study reports for the ﬁrst time that TBC1D1,
known to be involved in the insulin response in muscle and adi-
pose tissue, is expressed in beta-cells, is phosphorylated in
response to glucose and is involved in beta-cell proliferation and
insulin release.
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